ARTICLE | Clinical News
Neovastat (AE-941): Began Phase III testing
January 24, 2000 8:00 AM UTC
Aeterna Laboratories Inc. (TSE:AEL), Quebec City, Quebec Product: Neovastat (AE-941) Business: Cancer Therapeutic category: Angiogenesis Target: Matrix metalloproteinases and VEGF Description: Oral b...